Arizona State Retirement System Grows Position in Nuvation Bio Inc. (NYSE:NUVB)

Arizona State Retirement System increased its position in shares of Nuvation Bio Inc. (NYSE:NUVBFree Report) by 47.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 62,964 shares of the company’s stock after buying an additional 20,176 shares during the quarter. Arizona State Retirement System’s holdings in Nuvation Bio were worth $167,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in NUVB. GSA Capital Partners LLP purchased a new position in Nuvation Bio during the 3rd quarter worth approximately $172,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Nuvation Bio by 9.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 396,736 shares of the company’s stock valued at $909,000 after purchasing an additional 32,811 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Nuvation Bio in the 3rd quarter valued at approximately $132,000. Charles Schwab Investment Management Inc. grew its stake in shares of Nuvation Bio by 4.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,394,015 shares of the company’s stock valued at $3,192,000 after purchasing an additional 60,590 shares during the last quarter. Finally, Meridian Wealth Management LLC grew its stake in shares of Nuvation Bio by 47.0% in the 3rd quarter. Meridian Wealth Management LLC now owns 82,840 shares of the company’s stock valued at $190,000 after purchasing an additional 26,495 shares during the last quarter. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Nuvation Bio Price Performance

NUVB opened at $2.14 on Monday. The business has a 50 day simple moving average of $2.35 and a 200-day simple moving average of $2.55. The stock has a market capitalization of $723.08 million, a P/E ratio of -0.98 and a beta of 1.47. Nuvation Bio Inc. has a 12 month low of $1.67 and a 12 month high of $4.16.

Wall Street Analysts Forecast Growth

NUVB has been the topic of several analyst reports. Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of Nuvation Bio in a research note on Monday, March 3rd. Jones Trading initiated coverage on Nuvation Bio in a research note on Wednesday, March 12th. They issued a “buy” rating and a $10.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Finally, HC Wainwright lowered their target price on Nuvation Bio from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $8.33.

Read Our Latest Stock Analysis on NUVB

Nuvation Bio Profile

(Free Report)

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Further Reading

Want to see what other hedge funds are holding NUVB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc. (NYSE:NUVBFree Report).

Institutional Ownership by Quarter for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.